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a  b  s  t  r  a  c  t
Since  the  innovation  of  epoprostenol,  a prostacyclin  analog,  providing  treatment  for pulmonary  arte-
rial  hypertension  (PAH)  in  the  1990s,  two types  of oral  drugs,  endothelin  receptor  antagonists  (ERAs)
and  phosphodiesterase  V inhibitors,  have  further  improved  therapy  for  PAH.  In  contrast,  it has  become
clear  that  the  efﬁcacy  of monotherapy  with  these  drugs  is  limited,  and  the establishment  of  combinationeywords:
ombination therapy
onotherapy
ulmonary arterial hypertension
therapies  should  be  considered  for PAH.  Given  that  the  newest  PAH  drugs  include  a  receptor  tyrosine
kinase  antagonist  (imatinib),  a  soluble  guanylate  cyclase  stimulator  (riociguat),  an  oral  analog  of  pros-
tacyclin (selexipag),  and  a tissue  targeting  ERA (macitentan)  determination  of appropriate  combinations
for  various  etiologies  and  clinical  stages  is urgently  required.  In the  next  decade,  it can  be expected  that
the discovery  of efﬁcacious  combination  therapies,  involving  old  and  new  drugs,  will  lead  to  signiﬁcant
advances  in  the  treatment  of  PAH.©  2012  Japanese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
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. Introduction: history of progress in the treatment of
ulmonary arterial hypertension
The present understanding of pathophysiological abnormali-
ies in pulmonary arterial hypertension (PAH) and corresponding
argets of PAH drugs is summarized in Fig. 1, which is generated
rom accumulated data on pulmonary hypertension (PH). In 1891,
H was reported as “pulmonary vascular sclerosis” for the ﬁrst
ime by Ernst von Romberg, a German physician and pathologist,
lthough blood pressure could not be measured at that time. Dur-
ng the early 1900s, the concept of hemodynamics was  proposed
y physiologists and physicians including Otto Frank and Ernest
. Starling, the names of whom are now well known in cardiol-
gy through Frank–Starling’s law. Subsequent efforts to understand
emodynamics led to the invention of the Swan–Ganz catheter
n 1970, which established a method for bed-side measurement
f hemodynamics in patients with PH and heart failure. Until the
950s, vasoconstriction of the pulmonary vasculature was reported
o cause PH, which was  reproduced in experiments with hypoxic
tress and shown to be relieved by the vasodilators tolazoline [1]
nd acetylcholine [2].  In 1973, the ﬁrst World Health Organiza-
ion (WHO) Meeting on the topic was held in Geneva, Switzerland,
nd the pressure-rise in pulmonary arteries was classiﬁed into two
ategories: primary pulmonary hypertension (PPH) and secondary
H. A more detailed classiﬁcation of PH was deﬁned at the sec-
nd WHO  symposium (Evian, France) in 1998, where the term
AH was deﬁned. Between the two meetings, calcium antagonists
ere succeeded by the prostacyclin analog epoprostenol as a treat-
ent for PAH, and epoprostenol became the ﬁrst primary drug for
atients with PAH. Treatment with intravenous epoprostenol dra-
atically improved the survival rate of patients with PPH. However,
he beneﬁts of epoprostenol remain limited with only a 60% sur-
ival rate after 3 years [3].  In 1986, Furchgott et al. discovered
hat the previously termed endothelium-derived relaxing factor
ERDF) was indeed nitric oxide (NO). It is now recognized that in
atients with PAH, diminished NO synthesis is accompanied by
n increase in the major cyclic guanine monophosphate (cGMP)
etabolizing enzyme phosphodiesterase (PDE)-V. This results in
arked depletion of cGMP in smooth muscle cells, and ﬁnally, a
uppressed ability to prevent vasoconstriction and cell prolifera-
ion (Fig. 1). In 1988, Yanagisawa et al. [4] discovered endothelin-1
ET-1), which was overexpressed in the pulmonary arteries of
atients with PH [5].  It is now known that ET-1 induces not only
trong vasoconstriction through a calcium-sensitive pathway as
ell as a calcium-dependent pathway, but also cell proliferation
hrough mitogen-activated protein (MAP) kinase activation (Fig. 1).
ence, these two impaired pathways became therapeutic targets
or patients with PAH, leading to the development of the ET-1
eceptor antagonist (ERA) bosentan and recruitment of the PDE-
 inhibitor sildenaﬁl. Both of these drugs have beneﬁted patients
ith PAH since the year 2000 [6,7]. At the fourth WHO  meeting
Dana Point, CA, USA) in 2008, the current therapeutic algorithm
as designed, presenting prostanoids, ERAs, and PDE-V inhibitors
s the main regimens for the treatment of PAH. These three types
f drugs continue to play a pivotal role in the treatment of PAH.
n addition at that meeting, the clinical classiﬁcation of PH was
evised, and PPH was subcategorized into idiopathic and heritable
AH.
. Monotherapy with a prostanoid, an ERA, or a PDE-V
nhibitorIn the current guidelines of the European Society of Cardiology
ESC) [8],  and the American College of Cardiology/American Heart
ssociation (ACC/AHA) [9],  the ﬁrst choice of drug treatment isy 60 (2012) 344–349 345
recommended according to the evidence and severity of the disease
(WHO functional class). In addition, adverse effects and drug–drug
interactions are considered as described below.
In a meta-analysis, Galie et al. [10] pooled data from placebo-
controlled trials and evaluated the efﬁcacy of each PAH drug in
terms of mortality. They calculated a 40% improvement in survival
with monotherapy or by adding one drug to the ongoing ther-
apy. This improvement is considered modest because 60% of the
patients could not be saved. This result requires an assessment of
an initial combination therapy in prospective randomized control
trials.
2.1. Prostacyclin/prostaglandin I2 derivatives
Prostacyclin/prostaglandin I2 (PS) that is produced by endothe-
lial cells is a potent systemic and pulmonary vasodilator and
a powerful inhibitor of platelet aggregation. These actions are
mediated through its binding to G-protein-coupled receptors, sub-
sequent activation of adenylate cyclase, and increased production
of intracellular cyclic-adenosine monophosphate (cAMP). This in
turn causes decreases in intracellular Ca2+, and diminishes Ca2+
sensitivity of myoﬁlaments (Fig. 1). In patients with idiopathic
pulmonary arterial hypertension (IPAH), the expression of PS syn-
thase is reportedly downregulated [11], and overexpression of PS
synthase protects against the emergence of PH in hypoxic mice
[12]. After the development of stable PS analogs, epoprostenol
became the ﬁrst drug with proven beneﬁts in patients with
PAH [13]. Currently, all PS derivatives except beraprost (Fig. 1)
are recommended for patients with severe PAH (WHO III/IV)
[8,9].
2.1.1. Epoprostenol
Due to its short half-life (approximately 6 min  in the blood),
epoprostenol must be dissolved in alkaline solution, kept cool and
protected against light, and continuously pumped into the blood
through a subcutaneously implanted central venous line attached
to a mobile pump. As a treatment for PAH, epoptostenol com-
pensates the deﬁcit of vasodilating native PS. At its inception, the
effects of epoprostenol on clinical outcomes seemed potentially
promising. However, these are now considered to be modest, with
improvements in survival rate by only 3 years in approximately
60% of patients [14]. Sitbon et al. also suggest that hemodynamic
improvements during the initial 3 months of epoprostenol treat-
ment may  predict long-term outcomes for patients with IPAH [15].
In contrast to these limitations, Akagi et al. have proposed that
a high dose of epoprostenol (more than 100 ng/kg/min) dramati-
cally improves hemodynamics in patients with IPAH as compared
with the regular dose (20–40 ng/kg/min) [16]. A high dose of
epoprostenol has been tested in the USA and has reportedly caused
high cardiac output (CO) syndrome, necessitating reduction of the
dose [17]. However, with the exception of extremely high CO, the
hemodynamic effect of epoprostenol in this study was similar to
that in the former study. The discrepancy in CO between the two
studies may  be due to the rate at which the dose was increased.
Further evaluation of high dose epoprostenol is necessary to assess
the greater hemodynamic improvements and improved prognosis
proposed by Sitbon et al. [15].
Among the adverse effects of epoprostenol, accelerated hypoxia
is a concern, especially in patients with serious chronic lung dis-
eases. Ghofrani et al. [18] have clearly shown that epoprostenol
increased shunt ﬂow in the lung, leading to accelerated ven-
tilation/perfusion mismatch, and hypoxia in patients with lung
ﬁbrosis. In contrast, sildenaﬁl did not alter, and may have even
improved arterial oxygen saturation. Theoretically, this adverse
effect may  also be relevant to other PS derivatives.
346 A. Yao / Journal of Cardiology 60 (2012) 344–349
Fig. 1. Developmental mechanisms and drug targets of pulmonary arterial hypertension. This ﬁgure comprehensively summarizes the molecular mechanisms involved
in  the development of pulmonary arterial hypertension (PAH), and thereby indicates targets of PAH drugs. The drug names in white have been approved and used in
patients  with PAH, drug names in black are not approved to date, but are under clinical trials. AC, adenylate cyclase; Ang-1, angiopoeitin; BMP, bone morphogenetic protein;
BMP-R,  bone morphogenetic protein receptor; [Ca2+]I, intracellular Ca2+ concentration; cAMP, cyclic AMP; cGMP, cyclic GMP; DAG, diacylglycerol; Em, membrane potential;
ET-1,  endothelin-1; 5HT, 5-hydroxytryptamine (serotonin); HTT, hydroxytryptamine (serotonin) transporter; IP3, inositol 1,4,5-trisphosphate; [K+], K+ concentration; Kv,
voltage-gated K+; MAPK, mitogen-activated protein kinase; NCX, sodium–calcium exchanger; NO, nitric oxide; NOS, nitric oxide synthase; PDE, phophodiesterase; PDGF,
platelet-derived growth factor; PGI2, prostacyclin; PIP2, phosphatidylinositol-4,5-diphosphate; PKA, protein kinase A; PKG, protein kinase G; PKC, protein kinase C; PLC,
p nels; R
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eceptor  (ligand) speciﬁc Smad; RTK, receptor tyrosine kinase; sGC, soluble guanyla
ndothelial-speciﬁc tyrosine kinase; VDCC, voltage-dependent calcium channel.
.1.2. Treprostinil
Continuous administration of treprostinil can be achieved not
nly intravenously with a similar system to epoprostenol, but also
ubcutaneously using a ﬁne needle-conjugated line connected to a
obile pump. Its advantage is that patients need not dissolve the
rug themselves, change the drug cassette daily, or keep the drug
olution cold. Otherwise, its clinical effects are similar to those of
poprostenol.
.1.3. Iloprost
Inhaled iloprost has been shown to beneﬁt patients with IPAH
WHO III–IV) [19]. However, inhalation is required as often as
–12 times per day. The clinical effects of iloprost are similar to
poprostenol and treprostinil, and superior to them with regard to
nducible infections.
.1.4. Beraprost
Beraprost was the ﬁrst oral drug for PAH [20,21], although its
ffects subside after half a year of use. Therefore, beraprost has
nly been approved and used in Japan.
.2. Endothelin receptor antagonists
Since ET-1 was discovered, its roles in the pathophysiology of
arious vascular diseases have been studied extensively [22]. Its
xpression has been found to increase in the lungs of patients with
H [5] concomitantly with overexpression of its receptors, ETA and
TB, on the membrane of smooth muscle cells, and depletion of ETB
n endothelial cell membranes. Through the ETA and ETB receptors,
T-1 causes not only vasoconstriction, but also induces prolifer-
tion of vascular smooth muscle cells in patients with PAH. InOCK, Rho associated coiled-coil containing protein kinase (Rho kinase); R-Smad,
lase; SOC, store depletion-operated Ca2+ channel; SR, sarcoplasmic reticulum; TIE,
contrast, depletion of ETB on endothelial cell membranes is thought
to contribute to vasoconstriction of the pulmonary artery through
an endothelial-dependent pathway. Hence, blockage of the ET path-
way has been shown in major clinical trials to improve clinical
features of patients with PAH [7,23,24]. According to recommenda-
tions of the guidelines [8,9], ﬁrst-line use of ERAs should be applied
to patients with mild to moderate PAH (WHO II/III).
2.2.1. Bosentan
Bosentan is a dual ETA and ETB receptor antagonist, and has
been approved as the ﬁrst oral drug for patients with PAH. As
described above, treatment with bosentan beneﬁts patients with
mild to moderate PAH [7,23].  However, bosentan caused hepatic
injury with a frequency of approximately 10% [7,23], whereas
ambrisentan did not cause any serious elevation of hepatic enzymes
[24,25]. Chronic use of bosentan reportedly causes overexpression
of CYP3A4 and CYP2C9, which results in decreased plasma con-
centrations of co-administered sildenaﬁl [26] and tadalaﬁl [27].
However, the consequent adverse drug interactions that reduce
the efﬁcacy of sildenaﬁl and tadalaﬁl are not considered clinically
critical [23,28,29].  In contrast, the plasma concentration of bosen-
tan was reportedly increased by sildenaﬁl [30], but not by tadalaﬁl.
Nonetheless, these drug interactions do not strongly inﬂuence drug
choice, although consideration is important when administering
drugs that modify, or are modiﬁed, by the CYP-family.
2.2.2. Ambrisentan
Since sitaxsentan was removed from clinical use due to some
lethal events, ambrisentan has been the only selective ERA against
the ETA receptor. In spite of its selectivity, the clinical beneﬁt of
ambrisentan is basically similar to bosentan. The most important
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linical difference between these drugs is related to adverse effects
n the liver, which are mild for ambrisentan [24]. Therefore,
atients with PAH and concomitant liver injury should be treated
ith ambrisentan if ERA therapy is chosen. In addition, ambrisentan
oes not inﬂuence the CYP system by itself, although it is metab-
lized by CYP3A4 and CYP2C9, suggesting that modiﬁers of the
YP-system such as cyclosporin should be co-prescribed with care.
therwise, the clinical activity of ambrisentan is similar to that of
osentan.
.3. Phosphodiesterase V inhibitors
Since NO was identiﬁed as an ERDF, it has been clear that NO
roduced by endothelial cells directly binds and activates solu-
le guanylate cyclase (sGC). This leads to enhanced production of
GMP, further activation of cGMP-dependent protein kinase (PKG),
nd subsequent relaxation of vascular smooth muscle cells and
asodilatation (Fig. 1). In the lung, NO is produced by vascular
nd airway epithelium, and exerts a vasodilating effect. Increased
xpression of the main cGMP metabolizing enzyme PDE-V has been
eported in patients with PAH, providing a target for the treat-
ent of this disease [31]. The selective PDE-V inhibitor sildenaﬁl,
hich had been already available for patients with erectile dysfunc-
ion, was recruited as a PAH treatment. The SUPER-1 trial [6] has
learly shown the effectiveness of sildenaﬁl in patients with PAH.
ith this result, the guidelines recommend ﬁrst-line use of PDE-
 inhibitors for patients with mild to moderate PAH (WHO II/III)
8,9].
One of the advantages of PDE-V inhibitors is to preserve cGMP
roduced by NO-sGC system and increase blood ﬂow into the well-
entilated lung, because the most prominent stimulus for local NO
roduction is alveolar distension during inspiration [32]. There-
ore, PDE-V inhibitors improve ventilation/perfusion matching by
ncreasing blood ﬂow into well-ventilated airways. This was indeed
hown in sildenaﬁl-treated patients with PH and lung ﬁbrosis [18].
.3.1. Sildenaﬁl
Sildenaﬁl is the ﬁrst PDE-V inhibitor available for patients
ith PAH. According to the SUPER-1 trial [6],  high doses of
ildenaﬁl did not improve the “6-min walk distance” (6MWD)
chieved with low-dose sildenaﬁl (20 mg  × 3 per day), whereas
emodynamic parameters [mean pulmonary arterial pressure
mPAP), CO, and pulmonary vascular resistance (PVR)] were
mproved by the highest dose (80 mg  × 3 per day). This result
an be partly explained by the fact that the acute vasodilating
ffect of sildenaﬁl is limited and not dose-dependent. Wilkins
t al. [33] have shown that the maximal vasodilating effect
f sildenaﬁl was achieved at 25 mg,  and treatment with more
han 100 mg  no longer induced additional vasodilation. However,
his result cannot explain the hemodynamic improvements in
atients with PAH chronically treated with high-dose sildenaﬁl
80 mg  × 3 per day). Thus, chronic effects of high-dose silden-
ﬁl may  be favorable to those of low-dose sildenaﬁl, although
he mechanisms behind this possibility remain to be eluci-
ated.
.3.2. Tadalaﬁl
Next to sildenaﬁl, tadalaﬁl has been approved for its clinical use
n patients with PAH, according to the results of the PHIRST trial
28]. Characteristics of tadalaﬁl include a long half-life (approx-
mately 17–18 h), making possible once daily administration of
0–40 mg.  The PHIRST trial also showed near signiﬁcant beneﬁts of
adalaﬁl in addition to on-going treatment with bosentan, despite
he likely bosentan-mediated upregulation of major metabolizing
nzymes (CYP3A4 and CYP2C9) that may  reduce plasma concen-
rations of tadalaﬁl. While tadalaﬁl is not as well characterizedy 60 (2012) 344–349 347
as sildenaﬁl, its clinical effectiveness does not appear inferior to
sildenaﬁl.
3. Combination therapy
Several small studies indicate the beneﬁts of combination
therapy for PAH, irrespective of the stability or severity of the
disease. These include studies of sildenaﬁl added to bosen-
tan [29,34], sildenaﬁl added to subcutaneous treprostinil [35],
bosentan added to sildenaﬁl (sub-analysis of the EARLY study
[23]), bosentan added to subcutaneous treprostinil [36], bosen-
tan added to intravenous epoprostenol [37], and others. The effect
of inhaled iloprost added to bosentan was examined in a ran-
domized, placebo-controlled, double-blind, and prospective trial
of 67 patients with relatively severe [New York Heart Associa-
tion (NYHA) III, 94%] PAH. This study showed that NYHA class,
mPAP, and PVR were signiﬁcantly improved, along with a ten-
dency to signiﬁcant improvement in 6MWD  [38]. Collectively,
these reports support the use of co-treatments with existing PAH
drug regimens in order to achieve the best possible clinical sta-
tus.
A review by Rich et al. indicated that histopathological indi-
cators are generally not improved by epoprostenol, even in
stable IPAH patients. However, there have been some reports of
histopathologically reversed remodeling in PH patients that had
been stabilized for a long time with a calcium antagonist [39]. The
PACES-1 trial [40] was  carried out to assess the effects of silden-
aﬁl co-prescribed for stable PAH patients using epoprostenol. In
this trial, sildenaﬁl signiﬁcantly improved hemodynamic parame-
ters and prolonged the time to clinical deterioration. Furthermore,
no deaths occurred in the sildenaﬁl co-treated group, whereas 7
patients died in the control group during the 4-month observa-
tion period. We  have recently reported that upfront combination
therapy with rapid titrations of bosentan, tadalaﬁl, and beraprost
to maximal doses almost normalized hemodynamic parameters
in a patient with severe IPAH in about half a year, who initially
did not respond to the NO inhalation vasoreactivity test. Follow-
ing the marked improvement in hemodynamics, exercise tolerance
was also normalized (peak VO2 25 ml/kg/min). Clinically, this indi-
cates reverse remodeling in pulmonary vasculature, as well as
improved cardiac function [41]. These reports unanimously imply
that monotherapy is only sufﬁcient for restricted patients with PAH,
and suggest the necessity of combination therapy, especially for
patients with severe PAH.
Recently, upfront combination therapies have been thought to
have greater beneﬁts in some speciﬁc cases than goal-oriented
target therapy (GOTT). In GOTT, PAH drugs are administered one
by one, and are superseded upon failure of clinical outcomes
such as those outlined in WHO  II; 2.5 L/min cardiac index, longer
6MWD,  etc. In this way, GOTT deprives subjects of the beneﬁts of
combination therapy. Upfront combination therapy may  improve
patient survival and quality of life. Indeed, our case report of
the upfront/programmed triple combination shows such poten-
tial; with complete remission of a patient with severe IPAH [41].
Moreover, Kemp et al. [42] have reported that initial combination
therapy with epoprostenol and bosentan in patients with severe
PAH is associated with improvement in clinical outcomes (func-
tional class, exercise capacity, hemodynamics, and transplant-free
survival), as compared with epoprostenol monotherapy.
Currently, randomized controlled trials (RCT) that are designed
to evaluate different combinations are underway. To generalize the
beneﬁts of combination therapies, we await the results of these
trials. However, it is unclear how many trials are necessary, how
many patients with PAH are required, and how long it will take to
complete clinical trials for all the combinations.
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. New drugs
.1. Imatinib
Imatinib has been used for the treatment of chronic myel-
genous leukemia (CML). This drug is a competitive antagonist
f the ATP-binding site of tyrosine kinase molecules such as the
eceptor tyrosine kinase of platelet derived growth factor (PDGF),
-Kit, c-abl, v-abl, and bcl-abl in CML. In addition to PS-, ET-1-,
nd NO-dependent pathways, the overexpression of PDGF and its
eceptor has been reported to play a pivotal role in the pathophy-
iology of PAH [43,44]. Schermuly et al. [44] reported that imatinib
mproved the survival rate of rats with monocrotaline-induced
H by decreasing pulmonary arterial pressure, and histologically
eversing diseased arteries. Ghofrani et al. [43] have performed
 phase II trial to determine the beneﬁts of imatinib in patients
ith PAH, leading to a phase III RCT (IMPRES study), the results
f which have not been published to date. We  have reported that
matinib improved the diffusion capacity of the lung for carbon
onoxide (DLCO), which is consistent with the improvement of
xygen saturation of the artery shown in the phase II trial [43],
n patients with IPAH and systemic sclerosis (SSc)-associated PAH
45]. In addition, we have shown an improvement in skin thickness,
ontraction of phalanges, Rayaud’s symptom, and nail-fold bleed-
ng in patients with SSc-associated PAH [46]. Recently, Overbeek
t al. [47] demonstrated that the expression and autophosphory-
ation of PDGF receptors was predominantly observed in the small
essels that neighbor the capillaries in patients with SSc-PAH, as
ompared with IPAH. These data imply favorable effects of imati-
ib in SSc-PAH, which is recognized as the most critical PAH, and
esponds poorly to available drugs. Further trials are required to
onﬁrm this assertion.
.2. Riociguat
Riociguat directly and NO-independently accelerates the pro-
uction of cGMP through direct stimulation of an intracellular sGC
48], the effect of which can be further augmented synergistically
ith NO when it exists [49]. This vasodilating effect favorably works
n patients with PAH, and indicates the possibility of combined
se with PDE-V inhibitors that may  lead to a strong stimulation of
GMP-dependent vasodilatation. A phase II trial with riociguat indi-
ates beneﬁcial effects including reduction in mPAP and PVR, and
n increase in CO in patients with PAH and chronic thromboem-
olic PH (CTEPH) [50]. To date, three types of RCT with riociguat
ave been initiated, namely, PATENT for patients with PAH, CHEST
or inoperable CTEPH, and LEFT for patients in the 2nd group of the
H classiﬁcation.
.3. Selexipag
Selexipag, a prostacyclin analog, is an oral prostacyclin (prosta-
randin I2)-receptor (IP-receptor) agonist. In contrast with other
rostanoids, selexipag is highly selective for human IP-receptors,
hereas other analogs of prostacyclin can activate other prostanoid
eceptors. Therefore, selexipag is thought to reduce the adverse
ffects induced by activation of prostanoid receptors other than IP-
eceptor, which may  further warrant the use of selexipag at high
oses. Indeed, a phase II trial has demonstrated its effectiveness in
atients with PAH [51]. Two RCTs of selexipag are underway; one
s for patients with PAH, and the other for patients with inoperable
TEPH. With this drug approved, triple oral combination therapy
ith an ERA, a PDE-V inhibitor, and a prostanoid would be available
or patients with PAH.
[
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4.4. Macitentan
Macitentan seems to belong to the next generation of
non-peptide and non-selective ERAs. The differences between
macitentan and bosentan can be summarized along three lines:
macitentan possesses outstanding tissue distribution, its receptor
binding capacity is superior to that of bosentan, and ﬁnally, maci-
tentan has fewer drug–drug interactions than bosentan. The ﬁrst
two properties may  allow reduced dosage, and the third may result
in improved tolerability. A phase III clinical trial is ongoing.
5. Conclusions
The current guidelines for treatment of PAH were established
in 2008 based on the evidence for a range of drugs. However,
the population of PAH-affected individuals is small (approximately
1:5000–10,000), and varied etiology hampers the performance of
RCTs for each combination therapy. In addition, new drugs are
becoming available for clinical use. Therefore, it seems almost
impossible to carry out RCTs for all the combination therapies.
National and other large registries such as REVEAL in the USA,
and CompERA in Europe and other countries including Japan, may
provide more reliable data on the efﬁcacy of each combination
therapy. Our strategy of combination therapy for PAH requires reg-
ular updates to accord with new guidelines and newly completed
RCTs. As described in this paper, combination therapy is most likely
to offer superior efﬁcacy to monotherapy. However, further stud-
ies are urgently required to determine optimal drug combinations
for treating PAH of varying etiology, and at various stages of PH
development.
References
[1] Dresdale DT, Michtom RJ, Schultz M.  Recent studies in primary pulmonary
hypertension, including pharmacodynamic observations on pulmonary vas-
cular resistance. Bull N Y Acad Med  1954;30:195–207.
[2] Harris P. Inﬂuence of acetylcholine on the pulmonary arterial pressure. Br Heart
J  1957;19:272–8.
[3] McLaughlin VV, Presberg KW,  Doyle RL, Abman SH, McCrory DC, Fortin T,
Ahearn G. Prognosis of pulmonary arterial hypertension: Accp evidence-based
clinical practice guidelines. Chest 2004;126:78S–92S.
[4] Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M,  Mitsui Y, Yazaki
Y,  Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vas-
cular endothelial cells. Nature 1988;332:411–5.
[5] Giaid A, Yanagisawa M,  Langleben D, Michel RP, Levy R, Shennib H, Kimura S,
Masaki T, Duguid WP,  Stewart DJ. Expression of endothelin-1 in the lungs of
patients with pulmonary hypertension. N Engl J Med  1993;328:1732–9.
[6] Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia
T,  Burgess G, Branzi A, Grimminger F, Kurzyna M,  Simonneau G. Sildenaﬁl citrate
therapy for pulmonary arterial hypertension. N Engl J Med  2005;353:2148–57.
[7] Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM,  Keogh A, Pulido T, Frost A,
Roux S, Leconte I, Landzberg M,  Simonneau G. Bosentan therapy for pulmonary
arterial hypertension. N Engl J Med  2002;346:896–903.
[8] Galie N, Hoeper MM,  Humbert M,  Torbicki A, Vachiery JL, Barbera JA, Beghetti M,
Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA,  Jondeau G, Klepetko W,  Opitz
C, Peacock A, et al. Guidelines for the diagnosis and treatment of pulmonary
hypertension: the task force for the diagnosis and treatment of pulmonary
hypertension of the European Society of Cardiology (ESC) and the European
Respiratory Society (ERS), endorsed by the International Society of Heart and
Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493–537.
[9] McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW,  Lindner JR, Math-
ier  MA,  McGoon MD,  Park MH,  Rosenson RS, Rubin LJ, Tapson VF, Varga J.
ACCF/AHA 2009 expert consensus document on pulmonary hypertension a
report of the American College of Cardiology Foundation Task Force on Expert
Consensus Documents and the American Heart Association developed in col-
laboration with the American College of Chest Physicians; American Thoracic
Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol
2009;53:1573–619.
10] Galie N, Palazzini M,  Manes A. Pulmonary arterial hypertension: from the
kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart
J  2010;31:2080–6.11] Tuder RM,  Cool CD, Geraci MW,  Wang J, Abman SH, Wright L, Badesch D, Voelkel
NF. Prostacyclin synthase expression is decreased in lungs from patients with
severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925–32.
12] Geraci MW,  Gao B, Shepherd DC, Moore MD, Westcott JY, Fagan KA, Alger
LA, Tuder RM,  Voelkel NF. Pulmonary prostacyclin synthase overexpression
diolog
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[A. Yao / Journal of Car
in  transgenic mice protects against development of hypoxic pulmonary hyper-
tension. J Clin Invest 1999;103:1509–15.
13] Rubin LJ, Mendoza J, Hood M,  McGoon M,  Barst R, Williams WB,  Diehl JH, Crow J,
Long W.  Treatment of primary pulmonary hypertension with continuous intra-
venous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern
Med  1990;112:485–91.
14] McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hyperten-
sion: the impact of epoprostenol therapy. Circulation 2002;106:1477–82.
15] Sitbon O, Humbert M,  Nunes H, Parent F, Garcia G, Herve P, Rainisio M,  Simon-
neau G. Long-term intravenous epoprostenol infusion in primary pulmonary
hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780–8.
16] Akagi S, Nakamura K, Miyaji K, Ogawa A, Kusano KF, Ito H, Matsubara H. Marked
hemodynamic improvements by high-dose epoprostenol therapy in patients
with idiopathic pulmonary arterial hypertension. Circ J 2010;74:2200–5.
17] Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac
output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol
1999;34:1184–7.
18] Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann
N,  Gunther A, Walmrath D, Seeger W,  Grimminger F. Sildenaﬁl for treatment
of  lung ﬁbrosis and pulmonary hypertension: a randomised controlled trial.
Lancet 2002;360:895–900.
19] Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho
S,  Speich R, Hoeper MM,  Behr J, Winkler J, Sitbon O, Popov W,  Ghofrani HA,
Manes A, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J
Med  2002;347:322–9.
20] Saji T, Ozawa Y, Ishikita T, Matsuura H, Matsuo N. Short-term hemodynamic
effect of a new oral pgi2 analogue, beraprost, in primary and secondary pul-
monary hypertension. Am J Cardiol 1996;78:244–7.
21] Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin
analogue in primary pulmonary hypertension. Lancet 1997;349:1365.
22] Bohm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in
cardiovascular disease. Cardiovasc Res 2007;76:8–18.
23] Galie N, Rubin L, Hoeper M,  Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic
A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary
arterial hypertension with bosentan (early study): a double-blind, randomised
controlled trial. Lancet 2008;371:2093–100.
24] Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB,
McGoon MD,  McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL,
Rubin LJ. Ambrisentan for the treatment of pulmonary arterial hypertension:
results of the ambrisentan in pulmonary arterial hypertension, randomized,
double-blind, placebo-controlled, multicenter, efﬁcacy (aries) study 1 and 2.
Circulation 2008;117:3010–9.
25] Oudiz RJ, Galie N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB,
McGoon MD,  McLaughlin VV, Roecker EB, Harrison BC, Despain D, Dufton C,
Rubin LJ. Long-term ambrisentan therapy for the treatment of pulmonary arte-
rial  hypertension. J Am Coll Cardiol 2009;54:1971–81.
26] Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR.  Bosentan decreases the
plasma concentration of sildenaﬁl when coprescribed in pulmonary hyperten-
sion. Br J Clin Pharmacol 2005;60:107–12.
27] Wrishko RE, Dingemanse J, Yu A, Darstein C, Phillips DL, Mitchell MI.  Pharma-
cokinetic interaction between tadalaﬁl and bosentan in healthy male subjects.
J  Clin Pharmacol 2008;48:610–8.
28] Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro
S,  White RJ, Chan M,  Beardsworth A, Frumkin L, Barst RJ. Tadalaﬁl therapy for
pulmonary arterial hypertension. Circulation 2009;119:2894–903.
29] Hatano M,  Yao A, Kinugawa K, Hirata Y, Nagai R. Acute effect of sildenaﬁl is
maintained in pulmonary arterial hypertension patients chronically treated
with bosentan. Int Heart J 2011;52:233–9.
30] Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic
interactions between steady-state bosentan and sildenaﬁl. Eur J Clin Pharmacol
2008;64:43–50.
31] Wharton J, Strange JW,  Moller GM,  Growcott EJ, Ren X, Franklyn AP, Phillips
SC,  Wilkins MR. Antiproliferative effects of phosphodiesterase type 5 inhibi-
tion in human pulmonary artery cells. Am J Respir Crit Care Med  2005;172:
105–13.
32] Ghofrani HA, Pepke-Zaba J, Barbera JA, Channick R, Keogh AM,  Gomez-Sanchez
MA,  Kneussl M,  Grimminger F. Nitric oxide pathway and phosphodie-
sterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol
2004;43:68S–72S.
33] Wilkins MR,  Wharton J, Grimminger F, Ghofrani HA. Phosphodiesterase
inhibitors for the treatment of pulmonary hypertension. Eur Respir J
2008;32:198–209.
[y 60 (2012) 344–349 349
34] Hoeper MM,  Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Com-
bination therapy with bosentan and sildenaﬁl in idiopathic pulmonary arterial
hypertension. Eur Respir J 2004;24:1007–10.
35] Gomberg-Maitland M, McLaughlin V, Gulati M,  Rich S. Efﬁcacy and safety
of  sildenaﬁl added to treprostinil in pulmonary hypertension. Am J Cardiol
2005;96:1334–6.
36] Benza RL, Rayburn BK, Tallaj JA, Pamboukian SV, Bourge RC. Treprostinil-
based therapy in the treatment of moderate-to-severe pulmonary arterial
hypertension: Long-term efﬁcacy and combination with bosentan. Chest
2008;134:139–45.
37] Akagi S, Matsubara H, Miyaji K, Ikeda E, Dan K, Tokunaga N, Hisamatsu K, Mune-
masa M,  Fujimoto Y, Ohe T. Additional effects of bosentan in patients with
idiopathic pulmonary arterial hypertension already treated with high-dose
epoprostenol. Circ J 2008;72:1142–6.
38] McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch
DB, Barst RJ, Hsu HH, Rubin LJ. Randomized study of adding inhaled iloprost
to  existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care
Med  2006;174:1257–63.
39] Rich S, Pogoriler J, Husain AN, Toth PT, Gomberg-Maitland M,  Archer SL.
Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic
pulmonary arterial hypertension. Chest 2010;138:1234–9.
40] Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer
MR,  Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB. Addition of sildenaﬁl
to  long-term intravenous epoprostenol therapy in patients with pulmonary
arterial hypertension: a randomized trial. Ann Intern Med  2008;149:521–30.
41] Maki H, Yao A, Inaba T, Shiga T, Hatano M,  Kinugawa K, Yamashita T, Aizawa
T,  Nagai R. Initial and programmed combination therapy with oral drugs
for  severe idiopathic pulmonary arterial hypertension. Int Heart J 2011;52:
323–6.
42] Kemp K, Savale L, O’Callaghan DS, Jais X, Montani D, Humbert M,  Simonneau G,
Sitbon O. Usefulness of ﬁrst-line combination therapy with epoprostenol and
bosentan in pulmonary arterial hypertension: an observational study. J Heart
Lung Transplant 2012;31:150–8.
43] Ghofrani HA, Morrell NW,  Hoeper MM,  Olschewski H, Peacock AJ, Barst RJ,
Shapiro S, Golpon H, Toshner M,  Grimminger F, Pascoe S. Imatinib in pul-
monary arterial hypertension patients with inadequate response to established
therapy. Am J Respir Crit Care Med  2010;182:1171–7.
44] Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov
A,  Lai YJ, Weissmann N, Seeger W,  Grimminger F. Reversal of experimental
pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811–21.
45] Hatano M,  Yao A, Shiga T, Kinugawa K, Hirata Y, Nagai R. Imatinib mesylate
has the potential to exert its efﬁcacy by down-regulating the plasma concen-
tration of platelet-derived growth factor in patients with pulmonary arterial
hypertension. Int Heart J 2010;51:272–6.
46] Tamaki Z, Asano Y, Hatano M,  Yao A, Kawashima T, Tomita M,  Kinugawa K,
Nagai R, Sato S. Efﬁcacy of low-dose imatinib mesylate for cutaneous involve-
ment in systemic sclerosis: a preliminary report of three cases. Mod Rheumatol
2012;22:94–9.
47] Overbeek MJ,  Boonstra A, Voskuyl AE, Vonk MC,  Vonk-Noordegraaf A, van
Berkel MP,  Mooi WJ,  Dijkmans BA, Hondema LS, Smit EF, Grunberg K. Platelet-
derived growth factor receptor-beta and epidermal growth factor receptor
in pulmonary vasculature of systemic sclerosis-associated pulmonary arte-
rial hypertension versus idiopathic pulmonary arterial hypertension and
pulmonary veno-occlusive disease: a case–control study. Arthritis Res Ther
2011;13:R61.
48] Stasch JP, Becker EM,  Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer
R,  Minuth T, Perzborn E, Pleiss U, Schroder H, Schroeder W,  Stahl E, Steinke W,
Straub A, et al. NO-independent regulatory site on soluble guanylate cyclase.
Nature 2001;410:212–5.
49] Schermuly RT, Stasch JP, Pullamsetti SS, Middendorff R, Muller D,  Schluter KD,
Dingendorf A, Hackemack S, Kolosionek E, Kaulen C, Dumitrascu R, Weiss-
mann N, Mittendorf J, Klepetko W,  Seeger W,  et al. Expression and function
of  soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J
2008;32:881–91.
50] Ghofrani HA, Hoeper MM,  Halank M,  Meyer FJ, Staehler G,  Behr J, Ewert R,
Weimann G, Grimminger F. Riociguat for chronic thromboembolic pulmonary
hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir
J  2010;36:792–9.
51] Simonneau G, Torbicki A, Hoeper MM,  Delcroix M,  Karlocai K, Galie N, Degano
B,  Bonderman D, Kurzyna M,  Efﬁcace M, Giorgino R, Lang IM.  Selexipag, an oral,
selective IP receptor agonist for the treatment of pulmonary arterial hyperten-
sion. Eur Respir J, 2012; erj01375-2011.
